Search - tctmd.com

Displaying 941 - 960 of 1798

Sort: Relevancy | Date

Presentation TCT 2018

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

Presenter: John A. Bittl, C. Michael Gibson, Matthew J. Price

September 23, 2018

Presentation TCT 2018

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

Presenter: John A. Bittl, C. Michael Gibson, Giuseppe Tarantini

September 23, 2018

Presentation TCT 2018

Featured Lecture: Does the Polypill Enhance Drug Adherence and Improve Cardiovascular Outcomes?

Presenter: John A. Bittl, C. Michael Gibson, Valentin Fuster

September 23, 2018

Presentation TCT 2018

Featured Lecture: The High-risk Patient: Risk Assessment and Current Recommendations for DAPT and OAC

Presenter: Bagrat Alekyan, Juan F. Granada, Roxana Mehran

September 22, 2018

Presentation TCT 2018

Clinical Trials for Short DAPT: FDA Perspective

Presenter: Christopher J Popma

September 22, 2018

Presentation TCT 2018

The Current Situation of DAPT for Coronary DES in US

Presenter: Mitchell W. Krucoff

September 22, 2018

Presentation TCT 2018

The Current Situation of DAPT for Coronary DES in Japan

Presenter: Hiroyoshi Yokoi

September 22, 2018

Presentation TCT 2018

Case Conclusion

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Presenter: Philip M. Urban, Robert W. Yeh, Michael A. Kutcher, Michelle O'Donoghue, Elmir Omerovic, Manel Sabate, Daniel I. Simon, Giuseppe Tarantini

September 22, 2018

Presentation TCT 2018

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Presenter: Philip M. Urban, Robert W. Yeh, Stephan Windecker

September 22, 2018

Presentation TCT 2018

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Presenter: Philip M. Urban, Robert W. Yeh, C. Michael Gibson

September 22, 2018

Presentation TCT 2018

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

Presenter: Philip M. Urban, Robert W. Yeh, Tullio Palmerini

September 22, 2018

News Conference News TCT 2018

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

Michael O'Riordan

September 21, 2018

Presentation TCT 2018

TCT-110: Incidence, predictors, and outcomes of DAPT disruption due to non-compliance versus bleeding after PCI: insights from the PARIS Registry

Presenter: George D. Dangas, Germano Di Sciascio, Kamilia Moalem

September 21, 2018

Presentation TCT 2018

Does Aspirin Have a Role in the Management of Patients Undergoing PCI?

Presenter: Jeroen J. Bax, Stephan Windecker, Patrick W. Serruys

September 21, 2018

Presentation TCT 2018

Atrial Fibrillation and ACS/PCI: The End of Triple Therapy?

Presenter: Jeroen J. Bax, Stephan Windecker

September 21, 2018

News Conference News ESC 2018

Latest SWEDEHEART Data Show Acute MI Mortality Rates Have Stagnated

Todd Neale

September 04, 2018

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2018

Caitlin E. Cox

September 04, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

Advertisement

Switching Dual Antiplatelet Therapy After PCI: Who, When, Why, and How?

Benefits of Pretreatment With Dual Antiplatelet Therapy Prior to PCI in Stable CAD and ACS: Myth or Reality?

Featured Lecture: Does the Polypill Enhance Drug Adherence and Improve Cardiovascular Outcomes?

Featured Lecture: The High-risk Patient: Risk Assessment and Current Recommendations for DAPT and OAC

Clinical Trials for Short DAPT: FDA Perspective

The Current Situation of DAPT for Coronary DES in US

The Current Situation of DAPT for Coronary DES in Japan

Case Conclusion

DAPT Duration Case Presentation #2: PCI in Stable CAD With LMCAD and MVD, Case Introduction

DAPT Duration Case Presentation #1: NSTEMI in a High Bleeding Risk Patient, Case Introduction

Stent Selection for 1-3 Month DAPT: Current Evidence, Ongoing Studies

Algorithmic Pharmacology Recommendations for the PCI Patient With Atrial Fibrillation

Latest Thinking on DAPT Duration: Balancing Risk vs Benefit

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

TCT-110: Incidence, predictors, and outcomes of DAPT disruption due to non-compliance versus bleeding after PCI: insights from the PARIS Registry

Does Aspirin Have a Role in the Management of Patients Undergoing PCI?

Atrial Fibrillation and ACS/PCI: The End of Triple Therapy?

Latest SWEDEHEART Data Show Acute MI Mortality Rates Have Stagnated

TCTMD’s Top 10 Most Popular Stories for August 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content